Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jun;11(6Suppl2):S132-S134.
doi: 10.5489/cuaj.4635.

Choosing the right sling for your patient

Affiliations
Review

Choosing the right sling for your patient

Stephen S Steele et al. Can Urol Assoc J. 2017 Jun.

Abstract

Recent data has demonstrated a one in five lifetime risk of a woman requiring stress urinary incontinence (SUI) surgery. Currently, most women opt for a synthetic midurethral sling (MUS), with over 3.6 million placed worldwide. This article attempts to identify whether a gold standard exists with regards to surgical correction of female SUI. When considering which sling type to use for which incontinent woman, the published data demonstrates excellent results for both synthetic mesh (retropubic or transobturator routes) and fascial pubovaginal slings for most patients. Intrinsic sphincter deficiency does appear to be better treated with the use of a retropubic approach, although still with less than stellar results. With little to differentiate, the treatment of most female SUI may be solely based on which sling the surgeon feels most comfortable performing. Currently, most urologists and gynecologists favour synthetic MUS over fascial slings in surgical-naïve patients; however, recent U.S Food and Drug Administration (FDA) warnings concerning the use of mesh in transvaginal surgery have patients questioning the safety of synthetic MUS for the treatment of SUI.

PubMed Disclaimer

Conflict of interest statement

Competing interests: Dr. Steele has been an advisor for Allergan and Astellas; a speaker for Abbott and Astellas; has received grants from Astellas and Pfizer; and has participated in clinical trials supported by Astellas and Pfizer. Dr. Bailly has been an advisor and speaker for, has received honoraria from, and has participated in clinical trials supported by Allergan, Astellas, and Pfizer.

References

    1. Hampel C, Wienhold D, Benken N, et al. Definition of overactive bladder and epidemiology of urinary incontinence. Urology. 1997;50:4–14. discussion 15–7. https://doi.org/10.1016/S0090-4295(97)00578-5. - DOI - PubMed
    1. Wu J, Matthews CA, Conover MM, et al. Lifetime risk of stress urinary incontinence or pelvic organ prolapse surgery. Obstet Gynecol. 2014;123:1201–6. https://doi.org/10.1097/AOG.0000000000000286. - DOI - PMC - PubMed
    1. Nager C. Midurethral slings: Evidence-based vs. the medicolegal system. Am J Obstet Gynecol. 2016;2014:708.e1–5. https://doi.org/10.1016/j.ajog.2016.04.018. - DOI - PubMed
    1. Richter HE, Albo ME, Zyczynski HM, et al. Retropubic vs. transobturator midurethral slings for stress incontinence. N Engl J Med. 2010;362:2066–76. https://doi.org/10.1056/NEJMoa0912658. - DOI - PMC - PubMed
    1. Serati M, Braga A, Athanasiou S, et al. Tension-free vaginal tape-obturator for treatment of pure urodynamic stress urinary incontinence: Efficacy and adverse effects at 10 year followup. Eur Urol. 2017;71:674–9. https://doi.org/10.1016/j.eururo.2016.08.054. - DOI - PubMed

LinkOut - more resources